Drug identity, approved role, and dual receptor action
Agomelatine is a prescription antidepressant, not an ordinary sleeping pill or a melatonin supplement. Current European Union product information authorizes it for major depressive episodes in adults; approved uses, strengths, and age restrictions may differ by country and product. Depression may include difficulty falling asleep, awakenings, early waking, or excessive sleep, but improvement in depression-related sleep symptoms is not the same as authorization to treat primary insomnia, jet lag, shift-work sleep disorder, or every circadian problem.
Its pharmacology combines agonism at melatonin MT1 and MT2 receptors with antagonism at 5-HT2C receptors, without monoamine reuptake inhibition as its principal mechanism. These receptor actions are thought to influence circadian signaling and to modulate noradrenaline and dopamine release in the frontal cortex. This profile differs from melatonin, ramelteon, selective serotonin reuptake inhibitors, sedating antihistamines, and benzodiazepines. A novel mechanism does not prove superior efficacy and does not justify describing the drug as “natural,” nonsedating, or exempt from safety monitoring.
Sleep evidence, subjective-objective differences, and causal boundaries
Randomized trials have usually recorded sleep outcomes within depression or other selected populations. A recent meta-analysis found a small average improvement in subjective sleep quality versus placebo but no significant increase in objectively measured total sleep time. Some sleep-onset measures and reports of insomnia were favorable, while somnolence was more frequent, and data for many objective and daytime outcomes were limited. Feeling that sleep improved, a lower depression score, and a polysomnographic change are separate outcomes and should not substitute for one another.
The antidepressant trial literature also contains heterogeneity, extensive industry sponsorship, and a tendency for published results to be more favorable than unpublished results. Comparative evidence does not establish that agomelatine is universally more effective than other antidepressants. Persistent insomnia still requires review of sleep opportunity, schedule, light, caffeine, alcohol, and other medicines, plus assessment for sleep apnea, restless legs, pain, nocturia, bipolar disorder, and self-harm risk. Cognitive behavioral therapy for insomnia may be pursued alongside appropriate care; a melatonin-receptor mechanism does not remove the need to identify the cause.
Bedtime administration, pharmacokinetic variation, and switching treatment
Agomelatine should be used exactly as prescribed and according to the current local product information. Some current labels use a once-daily bedtime regimen, but this is not an individualized dose recommendation and does not authorize an extra dose after a nocturnal awakening. A missed dose, uncertainty about whether a dose was already taken, or a continuing need to drive or perform hazardous work should not prompt self-redosing or a double dose the next day. When changing from another antidepressant, the previous SSRI or SNRI can still cause discontinuation symptoms and must be tapered according to that drug; the absence of routine tapering for agomelatine itself does not make abrupt withdrawal of every prior drug safe.
Absorption is rapid, with peak concentration usually reached within one to two hours, but absolute bioavailability is low and highly variable because of substantial first-pass metabolism. The average plasma half-life is about one to two hours, and the major metabolites are inactive. Food does not generally change mean bioavailability or absorption rate, although a high-fat meal can increase variability. Sex, oral oestrogens, smoking status, liver function, and metabolic interactions can all alter exposure. A short plasma half-life does not mean that the clinical effect lasts only a few hours or guarantee unimpaired driving, balance, or reaction time the next morning.
Liver injury, laboratory schedule, and urgent warning signs
Liver injury is among the most important preventable risks of agomelatine. Current European product information requires transaminase testing before treatment and again at about weeks 3, 6, 12, and 24, as well as when clinically indicated; the schedule restarts after a dose increase. Treatment should not begin when baseline ALT or AST is more than three times the upper limit of normal and should be stopped immediately if this threshold is exceeded during treatment. An elevated result also requires prompt repeat testing as directed. Feeling well, sleeping better, or having had normal past tests cannot replace scheduled laboratory monitoring.
Postmarketing reports include marked transaminase elevation, hepatitis, jaundice, and hepatic failure, with rare death or transplantation in patients with hepatic risk factors. Unusually dark urine, pale stools, yellow skin or eyes, right upper abdominal pain, or sustained new unexplained fatigue requires immediate cessation of further self-administration and urgent medical contact. Obesity, fatty liver disease, diabetes, substantial alcohol use, and other potentially hepatotoxic medicines complicate the risk assessment. Supplements marketed for “liver protection,” a few alcohol-free days, or delayed blood testing cannot offset this risk.
Interactions, mood surveillance, and daytime function
About 90% of agomelatine metabolism is through CYP1A2, with smaller contributions from CYP2C9 and CYP2C19. Potent CYP1A2 inhibitors such as fluvoxamine and ciprofloxacin are contraindicated in some current labels. Oestrogens, propranolol, and enoxacin may increase exposure, whereas rifampicin and heavy smoking can reduce it. A substantial change in smoking or smoking cessation should also be reported to the prescriber rather than answered by self-adjusting the dose. Alcohol is not advised, and all prescription medicines, nonprescription products, herbs, and supplements should be reviewed individually.
Depression itself and the early or changing phases of antidepressant treatment can involve suicidal thoughts, behavioral change, or temporary worsening, requiring observation by the patient, close contacts, and clinicians. Particular caution is needed with a history of mania, hypomania, or bipolar disorder; unusual activation, markedly reduced need for sleep, impulsivity, or grandiosity warrants prompt assessment. Common adverse reactions include headache, nausea, and dizziness, and somnolence, insomnia, abnormal dreams, anxiety, and fatigue can also occur. Feeling subjectively alert is not proof that driving or machine operation is safe.
Special populations, pregnancy and lactation, and overdose response
Hepatic impairment is contraindicated in current European labeling because even mild or moderate cirrhosis can produce very large increases in exposure. Clinical experience in moderate or severe renal impairment is limited and requires individualized assessment. In that labeling, efficacy has not been documented at age 75 years or older and use is not recommended; safety and efficacy are also not established in children and adolescents. Human pregnancy data are limited and use is generally avoided as a precaution. Decisions about continuing treatment or breastfeeding should weigh maternal benefit against infant risk; antidepressant treatment should not be stopped independently, and bedtime use does not imply zero exposure through milk.
Experience with overdose is limited. Reported features include upper abdominal pain, somnolence, fatigue, agitation, anxiety, tension, dizziness, cyanosis, and malaise, and there is no specific antidote for home use. Accidental ingestion, a duplicate dose, access by a child, or intentional overdose requires immediate contact with emergency or poison services, with the medicine name, strength, possible amount, timing, and co-ingestants available. Recovery in a reported high-dose case is not a safety threshold because co-medications, individual susceptibility, and liver function can change the outcome.
Follow-up, storage, and encyclopedia boundaries
Follow-up should track mood, interest, self-harm thoughts, actual sleep opportunity, sleep onset and awakenings, morning alertness, abnormal dreams, signs of mania, missed doses, alcohol, and smoking changes, alongside the scheduled liver-test results. If sleep appears better without corresponding improvement in depression, function, or safety, or insomnia persists after mood stabilizes, depression residuals, an independent insomnia disorder, sleep-disordered breathing, and circadian problems should be reconsidered. Signs of liver injury, imminent self-harm, mania, or severe functional impairment take priority over a routine appointment.
The medicine should remain in its labeled original pack or a compliant identifiable dispensing container, stored according to the local label and kept inaccessible to children, visitors, and people without a prescription. It should not be shared, resold, or replaced with an unverified product marketed as the same sleep aid. Indications, monitoring instructions, and contraindications change across jurisdictions and over time, so the current information for the actual product is controlling. This entry explains mechanism, sleep evidence, and safety boundaries; it does not provide a personal dose, promise to reset a body clock or increase deep sleep, replace CBT-I, treat every cause of insomnia, or substitute for liver testing and psychiatric follow-up.